Products Tafasitamab + Lenalidomide
Tafasitamab + Lenalidomide Phase 3 Active ⚡ Active Interest: 41/100
Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
Dec 23, 2022 → Apr 1, 2027
About Tafasitamab + Lenalidomide Tafasitamab + Lenalidomide is a phase 3 stage product being developed by Incyte for Large B-Cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT05429268. Target conditions include Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma.
What happened to similar drugs? 1 of 20 similar drugs in Large B-Cell Lymphoma were approved
Clinical Trials (5) NCT ID Phase Status Start Completion Indication NCT06760156 Phase 2 Recruiting Mar 19, 2025 Jan 1, 2028 Large B-cell Lymphoma NCT05788289 Phase 2 Terminated Mar 14, 2023 Aug 1, 2024 Mantle Cell Lymphoma NCT05429268 Phase 3 Active Dec 23, 2022 Apr 1, 2027 Large B-Cell Lymphoma NCT05222555 Phase 1/2 Active Jul 19, 2022 Nov 30, 2027 Diffuse Large B Cell Lymphoma NCT05351593 Phase 1/2 Recruiting Jun 8, 2022 Jun 30, 2026 CNS Lymphoma
Product Company Stage Hype Score Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Eli Lilly Phase 2 rituximab Celltrion Phase 1 YM155 Astellas Pharma Phase 2 enzastaurin + gemcitabine + rituximab + oxaliplatin Eli Lilly Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Johnson & Johnson Phase 2 VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Johnson & Johnson Phase 2 Epcoritamab + Epcoritamab, lenalidomide and rituximab AbbVie Phase 2 Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine AbbVie Phase 3 ABBV-525 AbbVie Phase 1 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab AbbVie Phase 1/2 Copanlisib + Venetoclax AbbVie Phase 1/2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 Epcoritamab + Lenalidomide AbbVie Phase 2 Venetoclax + Selinexor AbbVie Phase 1 Epcoritamab AbbVie Phase 1 Loncastuximab Tesirine and Epcoritamab AbbVie Phase 2 Epcoritamab + Epcoritamab, tafasitamab and lenalidomide AbbVie Phase 2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 bendamustine + navitoclax + rituximab AbbVie Phase 2 Epcoritamab AbbVie Phase 2